Daewon Pharmaceutical (003220) Fundamentals 2026 — Revenue Analysis | SniperIQ
Daewon Pharmaceutical (003220) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩162.3B, trading at ₩7570.00 on the KSC. This SniperIQ fundamentals page covers Daewon Pharmaceutical's valuation, profitability (net margin -0.7%), revenue (₩605.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Daewon Pharmaceutical's market cap?
Daewon Pharmaceutical (003220) has a market capitalization of approximately ₩162.3B, trading at ₩7570.00 on the KSC. Market cap moves with the live share price.
What is Daewon Pharmaceutical's P/E ratio?
Daewon Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Daewon Pharmaceutical?
Daewon Pharmaceutical runs a net profit margin of -0.7%, a gross margin of 44.6%, and an operating margin of -0.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Daewon Pharmaceutical generate?
Daewon Pharmaceutical reported revenue of ₩605.6B for fiscal year 2025, with net income of -₩1.4B and earnings per share (EPS) of -64.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Daewon Pharmaceutical pay a dividend?
Daewon Pharmaceutical offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Daewon Pharmaceutical financially healthy?
Daewon Pharmaceutical carries a debt-to-equity ratio of 0.70x and a current ratio of 1.18x, with a market beta of 0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Daewon Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Daewon Pharmaceutical (003220) the key facts are: market cap ₩162.3B, revenue ₩605.6B, 52-week range 7200-13670. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Daewon Pharmaceutical's full fundamentals live
Get Daewon Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.